|
B3GALNT2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.29440000332204E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.48780000045024E-07 |
| Normal-vs-Stage2 |
2.551600E-01 |
| Normal-vs-Stage3 |
7.50380002578765E-09 |
| Normal-vs-Stage4 |
1.34369959603475E-10 |
| Stage1-vs-Stage2 |
1.452120E-02 |
| Stage1-vs-Stage3 |
7.394000E-02 |
| Stage1-vs-Stage4 |
6.204300E-03 |
| Stage2-vs-Stage3 |
2.496300E-03 |
| Stage2-vs-Stage4 |
5.201900E-04 |
| Stage3-vs-Stage4 |
4.174800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.93249999838707E-08 |
| Normal-vs-AfricanAmerican |
9.983300E-04 |
| Normal-vs-Asian |
1.04249999743899E-08 |
| Caucasian-vs-AfricanAmerican |
8.955200E-01 |
| Caucasian-vs-Asian |
1.223170E-01 |
| AfricanAmerican-vs-Asian |
2.754200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.34059999999481E-05 |
| Normal-vs-Female |
1.70499999674334E-08 |
| Male-vs-Female |
6.504600E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.03249999999977E-07 |
| Normal-vs-Age(41-60Yrs) |
3.36729999994567E-07 |
| Normal-vs-Age(61-80Yrs) |
3.66750000000415E-05 |
| Normal-vs-Age(81-100Yrs) |
2.190000E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.853000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.649800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.634600E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.901200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.672600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.636600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.1964995660918E-10 |
| Classical-VS-Follicular |
1.793500E-04 |
| Classical-VS-Other |
7.854800E-01 |
| Classical-VS-Normal |
1.15189999982945E-07 |
| Tall-VS-Follicular |
2.19557705349871E-12 |
| Tall-VS-Other |
1.214370E-01 |
| Tall-VS-Normal |
<1E-12 |
| Follicular-VS-Other |
3.253600E-01 |
| Follicular-VS-Normal |
2.507600E-01 |
| Other-VS-Normal |
4.651900E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.27889999999875E-05 |
| Normal-vs-N1 |
8.40849612160355E-12 |
| N0-vs-N1 |
4.38680000000025E-05 |
|
|
